Literature DB >> 22231288

Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: defining criteria based on the juvenile arthritis disease activity score.

Alessandro Consolaro1, Giulia Bracciolini, Nicolino Ruperto, Angela Pistorio, Silvia Magni-Manzoni, Clara Malattia, Silvia Pederzoli, Sergio Davì, Alberto Martini, Angelo Ravelli.   

Abstract

OBJECTIVE: To determine cutoff values for defining remission, minimal disease activity, and parent and child acceptable symptom state in juvenile idiopathic arthritis (JIA) using the Juvenile Arthritis Disease Activity Score (JADAS).
METHODS: For the selection of cutoff values, data from a clinical database including 609 children with JIA were used. Optimal cutoff values were determined against external criteria by calculating the 75th percentile of cumulative score distribution and through receiver operating characteristic curve analysis. External criteria included formal definitions of inactive disease and minimal disease activity, subjective rating of remission by physicians, parents, and children, and rating of acceptable symptom state by parents and children. The choice of cutoffs was made based on clinical and statistical grounds. Cross-validation was performed using 4 JIA patient samples that included a total of 1,323 patients, and was based on assessment of construct, discriminant, and predictive validity.
RESULTS: With all versions of the JADAS, the cutoff score for classifying a patient as having inactive disease was 1, whereas the cutoff for classification of minimal disease activity was 2 for oligoarticular JIA and 3.8 for polyarticular JIA. Cutoffs for physicians', parents', and children's subjective rating of remission ranged from 2 to 2.3. Cutoffs for acceptable symptom state ranged from 3.2 to 5.4 for parents and from 3 to 4.5 for children. Results of cross-validation analyses strongly supported the selected cutoff values.
CONCLUSION: Cutoff values for classifying various disease states in JIA using the JADAS were developed. In cross-validation analyses, they proved to have good construct and discriminant validity and ability to predict disease outcome.
Copyright © 2012 by the American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22231288     DOI: 10.1002/art.34373

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  61 in total

Review 1.  Juvenile spondyloarthritis.

Authors:  Sabrina Gmuca; Pamela F Weiss
Journal:  Curr Opin Rheumatol       Date:  2015-07       Impact factor: 5.006

Review 2.  Outcome Scores in Pediatric Rheumatology.

Authors:  Gabriella Giancane; Silvia Rosina; Alessandro Consolaro; Nicolino Ruperto
Journal:  Curr Rheumatol Rep       Date:  2021-03-08       Impact factor: 4.592

Review 3.  Management of juvenile idiopathic arthritis: hitting the target.

Authors:  Claas Hinze; Faekah Gohar; Dirk Foell
Journal:  Nat Rev Rheumatol       Date:  2015-01-06       Impact factor: 20.543

Review 4.  [Back to school physical education despite rheumatism : Development and testing of a sport scientific-based physical education certification].

Authors:  M Hartmann; J Merker; S Schrödl; M König; M Georgi; C Hinze; A Schwirtz; J-P Haas
Journal:  Z Rheumatol       Date:  2018-10       Impact factor: 1.372

5.  2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis.

Authors:  Sarah Ringold; Sheila T Angeles-Han; Timothy Beukelman; Daniel Lovell; Carlos A Cuello; Mara L Becker; Robert A Colbert; Brian M Feldman; Polly J Ferguson; Harry Gewanter; Jaime Guzman; Jennifer Horonjeff; Peter A Nigrovic; Michael J Ombrello; Murray H Passo; Matthew L Stoll; C Egla Rabinovich; Rayfel Schneider; Olha Halyabar; Kimberly Hays; Amit Aakash Shah; Nancy Sullivan; Ann Marie Szymanski; Marat Turgunbaev; Amy Turner; James Reston
Journal:  Arthritis Care Res (Hoboken)       Date:  2019-04-25       Impact factor: 4.794

6.  2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis.

Authors:  Sarah Ringold; Sheila T Angeles-Han; Timothy Beukelman; Daniel Lovell; Carlos A Cuello; Mara L Becker; Robert A Colbert; Brian M Feldman; Polly J Ferguson; Harry Gewanter; Jaime Guzman; Jennifer Horonjeff; Peter A Nigrovic; Michael J Ombrello; Murray H Passo; Matthew L Stoll; C Egla Rabinovich; Rayfel Schneider; Olha Halyabar; Kimberly Hays; Amit Aakash Shah; Nancy Sullivan; Ann Marie Szymanski; Marat Turgunbaev; Amy Turner; James Reston
Journal:  Arthritis Rheumatol       Date:  2019-04-25       Impact factor: 10.995

7.  Safety and efficacy of etanercept and adalimumab in children aged 2 to 4 years with juvenile idiopathic arthritis.

Authors:  D Windschall; G Horneff
Journal:  Clin Rheumatol       Date:  2016-10-05       Impact factor: 2.980

8.  [Therapy of juvenile idiopathic arthritis in early adulthood with biologics: transition from pediatric to adult care].

Authors:  M Niewerth; K Minden; J Klotsche; G Horneff
Journal:  Z Rheumatol       Date:  2014-08       Impact factor: 1.372

9.  Physical activity, functional ability, and disease activity in children and adolescents with juvenile idiopathic arthritis.

Authors:  S Gueddari; B Amine; S Rostom; D Badri; N Mawani; M Ezzahri; F Moussa; S Shyen; R Abouqal; B Chkirat; N Hajjaj-Hassouni
Journal:  Clin Rheumatol       Date:  2014-03-22       Impact factor: 2.980

10.  [Remission in pediatric rheumatology].

Authors:  H-L Huppertz
Journal:  Z Rheumatol       Date:  2013-05       Impact factor: 1.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.